Cognition Therapeutics, Inc.
Financial Services · Biotechnology
Overview
Advancing Accessible Solutions for Complex Neurodegenerative Diseases. Protecting neurons to advance treatment for neurodegenerative diseases.
Funding and backers
Grants
$9.4M
9 grants · CORDIS
Backers
2
Maine Angels, Sofia Fund
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 1, 2021
Won a grant $1.6M · CORDIS
Sep 1, 2019
Won a grant $1.4M · CORDIS
Sep 30, 2018
Won a grant $360k · CORDIS
Sep 15, 2018
Won a grant $2.1M · CORDIS
Jun 15, 2018
Won a grant $1.5M · CORDIS
Sep 15, 2017
Won a grant $224k · CORDIS
Apr 1, 2017
Won a grant $1.7M · CORDIS
Sep 30, 2016
Won a grant $222k · CORDIS
May 15, 2016
Won a grant $224k · CORDIS
Jan 2008
Website went live first capture in the Wayback Machine
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | May 2021 | $1.6M | — | CORDIS |
| Grant | Sep 2019 | $1.4M | — | CORDIS |
| Grant | Sep 2018 | $360k | — | CORDIS |
| Grant | Sep 2018 | $2.1M | — | CORDIS |
| Grant | Jun 2018 | $1.5M | — | CORDIS |
| Grant | Sep 2017 | $224k | — | CORDIS |
| Grant | Apr 2017 | $1.7M | — | CORDIS |
| Grant | Sep 2016 | $222k | — | CORDIS |
| Grant | May 2016 | $224k | — | CORDIS |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
CND advances neurodiagnostics through skin biopsy testing, including the Syn-One Test, for neurodegenerative diseases.
Our Mission. Deliver medicines that transform the lives of patients with neurodegenerative diseases.
Modulo is decoding the neuroimmune system. Applying science and engineering to identify new treatment paths for neurodegenerative diseases.
Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
A biotech company dedicated to developing transformative medicines for people with neurodegenerative diseases using cutting-edge science…
ProJenX's mission is to make prosetin, a scientifically validated, first-in-class MAP4 kinase inhibitor, available for ALS and other…
Financials
Total raised
$9.4M
Latest round
Grant
Funding rounds
9
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Sofia FundVia a fund
9 portfolio companies: Manifold@UMinnPress, MNSBIR | Minnesota\'s SBIR/STTR Accelerator, Mhta and 6 more
Maine AngelsVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
New Data: Zervimesine for the Treatment of Dementia With Lewy Bodies and Alzheimer Disease Psychiatric Times
Cognition Therapeutics reveals promising phase 2 results for zervimesine in treating dementia with Lewy bodies and Alzheimer disease at AAIC 2025.
Read more
Report
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
- An additional five years of patent protection may be possible through a standard extension -...
Read more
Report
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3...
Read more
Report
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat...
Read more
Report
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates...
Read more
Report
The Myth of Pure Pathology in Neurodegenerative Diseases
The Myth of Pure Pathology in Neurodegenerative Diseases Neurology Advisor By: Anthony Caggiano, MD, PhD July 28, 2026
Read more
Report
The Myth of Pure Pathology in Neurodegenerative Diseases
Molecular profiling, biomarker detection, and in vivo imaging are reshaping how neurologists diagnose neurodegenerative diseases.
Read more
Report
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the...
Read more
Report
Why The Best Biotech Leaders Take It Personally
Why The Best Biotech Leaders Take It Personally Life Science Leader By: Lisa Ricciardi May 20, 2026
Read more
Report
Why The Best Biotech Leaders Take It Personally
Personal investment isn't a liability in biotech leadership, but rather, a competitive advantage, writes Lisa Ricciardi, CEO of Cognition Therapeutics.
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Pittsburgh
United States
HQ